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Background. Aproximatelly 30% of patients operated on for colorectal cancer (CRC), with an expectedly favourable prognosis
(Dukes A-B/T1–T4, N0, M0) suﬀer recurrence and/or die. Method. In order to determine if tumor microvascular density
(MVD) is a prognostic factor in CRC, samples from tumors of 104 Dukes A-B CRC patients were retrospectively studied.
Immunohistochemistrywasperformedforanti-CD34antibodytovisualizetumorvascularisation.MVDwasexpressedasthetotal
number of vessels and as the percentage of microvascular area. We calculated MVD with a morphometry program and performed
descriptive, bivariate, and survival statistics. Results. The mean number of vessels was 37.37/200x ﬁeld, and the mean vascular
area was the 3.972%. 30% of the patients with < 37vessels/ﬁeld, and 21% of the patients with > 37vessels/ﬁeld, experienced
recurrence/death. The 35% of patients with < 4% of vascular area died following recurrence, compared with 14% of patients with
≥4% of vascular area. These diﬀerences in % of vascular area were statistically signiﬁcant. Conclusion.M V De x p r e s s e da st h et o t a l
number of vessels had no a statistically signiﬁcant inﬂuence on the evolution of CRC. However, neoplasias with a greater % of
vascular were associated to a better outcome.
Copyright © 2009 Rafael Uribarrena A et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Despite the advances in diagnostic and therapeutic methods,
theglobalsurvivalrateforcolorectaladenocarcinoma(CRC)
is approximately 50% and has not substantially improved in
recent years [1]. It ranges 80%–90% in Dukes stage A, 60%–
80% in Dukes B, 30%–35% in Dukes C, and 5%–25% in
Dukes D [2–5] .T h em a i np r o g n o s t i cf a c t o ri nC R Ci st h e
presence or not of metastasis in the regional lymph nodes
[1, 6]. Paradoxically, 20%–35% of patients diagnosed with
CRC with negative lymph nodes (N0) based on conventional
histological techniques will suﬀer tumour recurrence within
5y e a r s[ 4, 5]. This leads us to ask what other possible prog-
nostic factors might inﬂuence the evolution of the disease.
The degree to which a tumour is vascularised, expressed
as microvascular density (MVD), also inﬂuences the evolu-
tion of CRC. In the majority of solid tumours, angiogenesis
is essential for tumour growth and for its locorregional
and remote extension [7, 8]. Initially, tumour growth is
independent of the vascular contribution, as the neoplasic
cells receive nutrition from the diﬀusion of oxygen and from
the nutrients in the surrounding tissues. This characterises
the prevascular phase of neoplasic growth, during which
the tumour is only a few millimetres in size and has little
capacity to disseminate. Subsequently, angiogenic substances
are released by the tumour cells and healthy host tissue
(ﬁbroblasts, endothelial cells, macrophages, plasma cells).
The angiogenic stimuli are varied and interrelated. They
include hypoxia, speciﬁc growth factors, and interleukins [7,
9–11].Followingthereleaseoftheangiogenicsubstances,the
endothelial cells migrate towards the tumour and proliferate
inside of it, forming capillaries. The newly formed vessels
are more porous, with fragmented basal membranes that
allow nutrients to pass to the tumour stroma and cancer2 Gastroenterology Research and Practice
cells to enter into the circulation. In this vascular phase, the
neoplasia grows quickly and the risk of remote metastasis
increases [7, 12]. Nevertheless, tumor vascularisation is but
a single step in the metastatic process. For remote metastasis
to occur, each of the independent steps of the process must
take place [13]. Furthermore, the increase of the tumour
vascularisation permits the entry of immune system cells,
that could limit tumor development.
There are various studies on the relationship between
vasculardensityandothertumorparameterssuchassurvival
and remote metastasis in tumours of the breast and prostate
gland, melanoma, and large-cell pulmonary carcinoma. In
most cases, a direct relationship was found between MVD
and metastasis, and an inverse relationship was found
between MVD and patient survival [14, 15]. More recently,
similar studies have been performed on colorectal cancer
(CRC). The results of those studies are controversial because
although the majority of them reported an association
between a greater microvascular density, remote metastasis,
and patient survival [16–28], others did not [29–31], and in
some cases, high MVD was associated with better prognosis
[32–35].
Perhaps because of this contradictory results and
although the majority tend to consider high MVD as a
negative prognostic factor, a consensus review performed
by the College of American Pathologists in 1999 on the
prognostic factors in CRC classiﬁed MVD as a prognostic
factors that required further study (category III) [36].
2. Methods
2.1. Patients. The retrospective study included 104 consec-
utive patients diagnosed with CRC in Dukes stages A and
B (T1–T4, N0, M0) in the University Clinic Hospital in
Zaragoza, Spain, and in the Provincial Hospital of Zaragoza.
Exclusion criteria were as follows: (1) the administration
of adjuvant radio and chemotherapy, (2) lymph node
metastasisdetectedbymeansoftheconventionalhistological
methods (i.e., H&E), (3) remote metastasis at the moment of
surgery, and (4) other neoplasias detected 5 years before or
after CRC diagnosis that could interfere with its evolution.
2.2. Immunohistochemistry. Tissue samples from each CRC
case were ﬁxed in 10% neutral formalin and embeded in
paraﬃn. The most representative portion of a tumour was
selected for processing. Five micron thick sections of tissue
were deparaﬃnised, hydrated, and placed in citrate buﬀer
(pH 6). Endogenous peroxidise activity was blocked of incu-
bation in 5% H2O2 in methanol. Antigen was demasked by
pressure boiling in citrate (Target Retrieval Solution, Dako-
cytomation, Glostrup, Denmark) for 10 minutes. In order
to ascertain tumour MVD, samples were blocked with horse
serum and then incubated in the cross-sections through
blocking serum (horse serum) and antiHuman Antibody
CD34 (1/0 Ac monoclonal, clon QBEND/10 Dakocytoma-
tion, Glostrup, Denmark), since blood vessels are CD34
positive (Figures 1 and 2, foci of low and high MVD). We
detected the antibody with the EnVision kit (Dakocytoma-
Figure 1: Low microvascular density foci.
Figure 2: High microvascular density foci.
tion), with diaminobenzidine as a developer, and nuclear
contrast staining with haematoxylin, as a chromogen.
2.3. Microscopic Study. The histological sections, immunos-
tained for AB CD34, were studied by two pathologist (JO,
PP), with a Leica DM 4000B microscope at a semipanoramic
focus of 10× in order to locate the tumoral areas that
contains the greater concentration of blood capillaries (hot
spots).
Hot spots were selected by discarding all of the zones in
which an increase in MVD was not intrinsically dependent
on tumour growth dynamics but on added circumstances
and/or complications and could be considered as reac-
tive (Figure 3). The ruled out zones were superﬁcial ero-
sion/ulceration, the circumferential margin of intratumour
necrosis foci, and host-tumour interface.
Images of eight selected ﬁelds within the hot spots were
captured at 200× (ocular 10×,o b j e c t i v e2 0 ×) with a Leica
DFC 480 digital camera. The images were archived serially,
ignoring the characteristics of individual CRC cases (e.g.,
evolution).
MVD was measured by counting the number of blood
capillaries/200×ﬁeld.Well-formedvascularstructures,rudi-
mentary vascular structures, and angioblasts, (i.e., all those
structures that were inmunoreactive for CD 34) were
included. The area of the vascularisation (cumulative area
of each and every one of capillary vessels compared with
the total area of the all ﬁeld) was quantiﬁed relative to the
t o t a lt u m o u ra r e ao fe a c hi m a g e dﬁ e l d( p e r c e n t a g eo fa r e a ) .Gastroenterology Research and Practice 3
Figure 3: High MVD in superﬁcial ulcerated area.
MVD quantiﬁcation was performed with ContImUZ 1.0
morphometryprogram,designedbytheDigitalImageTreat-
mentCentreattheUniversityofZaragoza,thatautomatically
calculates the Microvascularisation Density (MVD) of the
tumour, by counting the number of objects in the image,
by means of an automatic function with manual connection
(Figure 4, whole process).
2.4. Statistical Study. Descriptive statistics of tumor charac-
teristics included local inﬁltration: submucosa (T1), muscu-
lar(T2),meso(T3),andserosa-adjacentsorgans(T4);Dukes
stage A or B (C and D were excluded); vascular, lymph node,
and perineural invasion (yes or no); and MVD: expressed as
the total number of vessels and as percentage of the vascular
area; we also included tumour recurrence (yes or no) and
month of recurrence and death (yes or no) and month of
death.
Bivariate inferential statistics were performed to identify
diﬀerences between the patients with a high and low MVD.
We divided the patients in 2 groups according to the number
of vessels per “hot spot” and percentage of vascularised
area. As a cut point we used the arithmetic mean (> or
<37 vessels > or <4% of vascular area), relative to the
studied variables. Pearson’s chi-squared test was used, with
theYatescorrectionorFisher’sexacttestwhennecessary.The
Student t-test, variance analysis, the nonparametric Mann-
Whitney U test, and the Kruskal-Wallis test were also used,
for cases in which the ANOVA or the Kruskal-Wallis results
were signiﬁcant, between-group analyses using the Pearson
correlation coeﬃcient and the Spearman rank coeﬃcient to
ascertain which variables accounted for the diﬀerences. A
95% conﬁdence level was chosen for statistical analyses.
3. Results
Of the 104 cases studied, 56 were Dukes stage A and 48 were
Dukes stage B. According to local inﬁltration, 11 patients
were T1, 45 were T2, 32 were T3, and 16 were T4.
Table 1: Number of vessels relative to local invasion.
Number of vessels P-value
N Mean Kruskal-Wallis
Submcosa-T1 11 37.29
Muscular-T2 45 36.40 .918
Meso-T3 32 38.43
Serosa-T4 16 37.98
Table 2: Percentage of tumor-vascularised area relative to local
invasion.
%v a s c u l a r i s e da r e a P-value
N Mean Kruskal-Wallis
Submcosa-T1 11 3.966
Muscular-T2 45 3.687 .635
Meso-T3 32 4.421
Serosa-T4 16 3.981
The mean number of vessels per hot spot was 37.37
(range 14.9–74, standard deviation 9.75, median conﬁdence
interval 35.11–39.63), and the mean vascular area, expressed
as % of tumor area occupied by vessels, was 3.976% (range
1.155–16.111, standard deviation 1.909, median conﬁdence
interval 3.534–4.419).
In 28 cases (26.92%) there was recurrence of the disease
led to death. Recurrence occurred at a mean of 23.73 months
of follow-up, (range 2–82 months, standard deviation (SD)
±20.24 months, mean conﬁdence interval (CI) 14.75–32.7).
The bivariate inferential statistics was used to compare the
total number of vessels and the vascular area relative to the
Dukes stage, the local invasion (T stage) and the occurrence
of recurrence and death.
TheresultsoftheKruskal-Wallisdemonstratedthatthere
were not signiﬁcant diﬀerences in the number of vessels (P =
.918, >. 05) and in the percentage of the tumor vascularised
area (P = .635, >. 05) compared with the local invasion
(Tables 1 and 2).
We evaluated vascular invasion by neoplastic cells as
a prognostic factor in CRC. Neoplastic cell invasion was
detected in 5 of the 104 patients studied, and recurrence
occurred in 4 (80%) of those patients. Recurrence occurred
in 24 (24.24%) of the remaining 99 patients. According
to Fisher’s exact test to compare vascular invasion (No,
Yes), with cancer recurrence and death (No, Yes), we found
signiﬁcant diﬀerences between two groups. Patients with
tumour vascular invasion had a signiﬁcantly higher risk of
recurrence and death (P = .018).
We also compared the Dukes stage with the tumor
recurrence and death. In the Dukes A group (n = 56), 8
patients (14.3%) died due to recurrence of the disease. In
Dukes B group (n = 48) cases, 20 patients (41.7%) died
due to the CRC. Chi-square test indicated that there were
signiﬁcant diﬀerences between the Dukes A and Dukes B
patients, with Dukes B patients having a higher risk of CRC
recurrence (P value = .004). If we analyze local invasion,
survival rate in T1 was 90.90%, in T2 84.44%, in T3 62.50%,
and in T4 50.0%. T3 and T4 colorectal cancers had a4 Gastroenterology Research and Practice
Step 1: CD34 Step 2: Original Step 3: Channel. The image
turns into a grey scale
Step 4: Segmentation. The
image turns in black (back)
and white (vessels)
Step 5: Closure. The program
closes the identiﬁed vessels to
individualize them
Step 6: Fill up. Deletes little
spots inside the selection
vessels. This way the program
can calculate the vascular area
with more precision
Step 7: Selection. Only
objects over a determined area
are selected to be identiﬁed as
vessels
Step 8: Identiﬁcation.
individualizes each object
giving them a “label” or
colour, in order to count them
and to calculate their area
Figure 4: Automatic vessel counting with ContImUZ 1.0 morphometry program the whole process.
Table 3: Dukes stage relative to recurrence-death.
DUKES Recurrence-death P-value
No Yes Total Chi-square
A4 885 6
85.7% 14.3% 100.0% .004
B2 8 2 04 8
58.3% 41.7% 100.0%
Total 76 28 104
Table 4: Local inﬁltration (T) relative to recurrence-death.
Local inﬁltration Recurrence-death P-value
No Yes Total Chi-square
Submcosa-T1 10 1 11
90.9% 9.1% 100.0% .012
Muscular propia-T2 38 7 45
84.4% 15.6% 100.0%
Meso-T3 20 12 32
62.5% 37.5% 100.0%
S e r o s a - T 4 881 6
50.0% 50.0% 100.0%
Total 76 28 104
signiﬁcant association with tumor recurrence and death (P
value = .0446) (Tables 3 and 4).
The bivariate inferential statistics of the number of
vascular objects (<37, ≥37) and tumor recurrence and
Table 5: Number of vessels relative to recurrence-death.
Number of objects Recurrence-death P-value
No Yes Total Chi-square
<37 47 20 67
70.1% 29.9% 100.0% .500
≥37 29 8 37
78.4% 21.6% 100.0%
Total 76 28 104
Table 6: Percentage of vascular area relative to recurrence-death.
Vascular area % Recurrence-death P-value
NO YES Total Chi-square
<44 1 2 2 6 3
65.1% 34.9% 100.0% .040
≥43 5 6 4 1
85.4% 14.6% 100.0%
Total 76 28 104
death showed that there were no group diﬀerences regarding
recurrence and death. Survival rate was 70.1% in <37 vessels
perareagroup and78.4% in >37 group. Pearson’sChi square
test indicated that there were no signiﬁcant group diﬀerences
in survival relative to the number of vascular objects (P value
= .5000) (Table 5).
However, the bivariate inferential statistics for the vascu-
larised tumour area (<4%, ≥4%) and the colorectal cancer
recurrence and death showed that recurrence in <4% groupGastroenterology Research and Practice 5
was 34.9%, compared with the 14.6% in the ≥4% group.
Pearson’s Chi-square test demonstrated that there was a
signiﬁcant group diﬀerence in the survival relative to the
vascularised tumor area. Patients with higher vascularized
tumor area had a signiﬁcant association with a better
outcome (P value = .040) (Table 6).
4. Discussion
Other authors have previously reported that the main
prognostic factor in CRC is the presence or absence of
tumour metastasis in the regional lymph nodes [12, 13].
A decrease in CRC rate was observed between patients
with Dukes stages B (N0) and Dukes stage C (N1), with
survival rates of approximately 60%–80% and 30%–35%,
respectively [2, 3]. It is especially notable that about 30% of
the patients that are lymph node negative, based on routine
H&E analysis, die from recurrence of the disease [2–5]. In
this study, 14% of the patients with Dukes A CRC and 41%
with Dukes B CRC suﬀered tumour recidivism that led to
death.Thisrepresentsalmosta27%recurrencefortheDukes
Aa n dBg r o u p s .
Dukes stage and local tumour growth are contrasted and
widely accepted prognostic factors in CRC [2–5, 37, 38]. As
expected, a signiﬁcantly higher frequency of recidivism and
death was observed in cases classiﬁed as Dukes B (41%) than
Dukes A (14%).
We also examined the association between vascular
invasion and prognosis. The ﬁnding of neoplasic cells in the
blood vessels of the tumour was associated with an increase
of tumour recurrence and survival reduction. Blood ﬂow to
the tumour is necessary for remote metastasis to occur and
our ﬁnding agrees with the majority of literature pertaining
to CRC prognostic factors [39–42].
There are several studies with contradictory results
regarding MVD as a prognostic factor in CRC. In the major-
ity of reports, increase in tumour vascularisation favours the
growth and remote dissemination of the cancer cells and is,
therefore, a predictor of poor outcome in CRC [16–28]. On
the other hand, some authors have reported higher survival
rates in tumours with high MVD. According to those studies,
a higher MVD would induce a greater immune response
that could slow tumour growth and dissemination [32–
35]. Finally, other published studies reported no relationship
between tumour vascularisation and the evolution of CRC
[29–31].
One of the advantages of immunohistochemistry is the
possibility of using tissue samples preserved in paraﬃn,
which permits retrospective studies, as in our case [43]. To
evaluate tumour vascularisation, MVD was determined by
calculating the total number of vessels (number of objects)
in the areas of greatest CD 34 immunoreactivity, that is, the
areas with the higher number of capillary vessels or “hot
spots.” Using this technique, the total number of vascular
elements was considered, without diﬀerentiating their size.
We also evaluated the MVD by determinating the percentage
of the total tumor area that was vascularised. In that way, it
was possible to diﬀerentiate microvessels from macrovessels,
w h i c hg a v eu sam o r ep r e c i s em e a s u r eo ft h et r u ed e g r e e
of vascularisation. As a cutoﬀ point for the survival study,
the arithmetic mean of number of vessels (37/ﬁeld) and
vascularised area per “hot spot” (4%) of all patients was
used.Inordertoincreaseaccuracy,thenumberofvesselsand
the percentage of vascular area were evaluated in eight hot
spots.
Compared with other studies, the present study intro-
duces three novel approaches. Firstly, we calculated the
numberofvesselsandthevascularareawithasemiautomatic
procedure (digital photography with a Leica DFC 480
camera and image analysis with an automatic quantiﬁcation
program ContImUZ). In this way, accuracy and objectivity
were increased compared with semiquantative calculation
which quantiﬁes MVD as low, medium, or high [21, 23, 24].
Secondly, the area of vascularisation may better represent
the true extent of tumor vascularisation, as considering only
that the total number of vessels may induce a skewed result.
That is, many of the vessels may be of scant calibre, and
the MVD may be, in fact, much lower than calculated.
Finally, “hot spots” were always chosen from ﬁelds away
from the tumour margins, the host-tumour interface, areas
of superﬁcial erosion/ulceration, and the circumferential
margin of necrosis foci. Those areas usually show increased
vascularisation relative to the reminder of the tumour and
may provide an erroneous idea of the true MVD.
Analysing the results of the bivariate analyses in relation
to the total number of vascular objects, we observed that
almost30%ofthepatientswith<37vessels/ﬁeldexperienced
tumour recurrence that led to death. This was the case
for 21% of the patients with >37 vessels/ﬁeld. However,
the diﬀerence was not statistically signiﬁcant. Therefore, we
concluded that the number of vascular objects in the ﬁelds
of greatest vascular density is not a prognostic factor in
CRC. We observed a signiﬁcant diﬀerence in recurrence
and survival relative to the MVD expressed as % of
vascular tumor area (% of tumor area occupied by vessels).
Thirty-ﬁve percent of patients with <4% vascular area died
followingtumourrecurrencecomparedwith14%ofpatients
with ≥4% vascular area. The patients who survived with
no recurrence had a signiﬁcantly larger vascularised area
compared with patients who had a poor evolution.
In conclusion, no signiﬁcant relationship was observed
between MVD, expressed as number of objects and tumor
recurrence and death. However, there was a signiﬁcant
statistical association between a higher % of vascular tumor
area and a more favourable prognosis. Dukes stage, local
inﬁltration, and vascular invasion by neoplastic cells can also
be considered as prognostic factors in CRC.
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